Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation

British Journal of Haematology

Volumn 92, Issue 4, 1996, Pages 847-854

  Xu, D ^a   Knaust, E ^a   Pisa, P ^a   Palucka, K ^a   Lundeberg, J ^b   Arestrom I ^a   Peterson, C ^a   Gruber, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

acute myelocytic leukaemia; cell sorting; mRNA; multidrug resistance; PCR

Indexed keywords

DAUNORUBICIN; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029922321     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.425963.x     Document Type: Article

References (28)

1. Barrand, M.A., Rhodes, T., Center, M.S. & Twentyman, P.R. (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. European Journal of Cancer, 29A, 408-415.
2. Brock, I., Hipfner, D.R., Nielsen, B.S., Jensen, P.B., Deeley, R.C., Cole, S.P.C. & Sehested, M. (1995) Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Research, 55, 459-462.
3. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
4. Chomczynski, P. & Sacchi, N. (1987) Single step method of RNA isolation by acid guanidin thiocyanate phenol chloroform extraction. Analytical Biochemistry, 162, 156-159.
5. Cole, S.P.C., Sparks, K.E., Fraser, K., Loe, D.W., Grant, C.E., Wilson, G.M. & Deeley, R.G. (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research, 54, 5902-5910.
6. Fojo, A.T. (1991) Multidrug resistance. Advances in Internal Medicine, 36, 195-218.
7. Galettis, P., Boutagy, J. & Ma, D.D.F. (1994) Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. British Journal of Cancer, 70, 324-329.
8. Gruber, A., Areström, I., Albertioni, F., Björkholm, M., Peterson, C. & Vitols, S. (1995a) Multidrug resistance (mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy. Leukemia and Lymphoma, 18, 435-442.
9. Gruber, A., Briese, B., Areström, I., Vitols, S., Björkholm, M. & Peterson, C. (1993) Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of mdrl gene expression. Leukemia Research, 17, 353-358.
10. Gruber, A., Larsson, R., Nygren, P., Björkholm, M. & Peterson, C. (1994) A non-P-glycoprotein mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia, 8, 985-989.
11. Gruber, A., Liliemark, E., Tidefelt, U., Paul, C., Björkholm, M., Peterson, C. & Liliemark, J. (1995b) Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia: relationship to treatment outcome and bone marrow toxicity. Leukemia Research, 19, 757-761.
12. Gruber, A., Vitols, S., Norgren, S., Areström, I., Peterson, C. Björkholm, M., Reizenstein, P. & Luthman, H. (1992) Quantitative determination of mdrl gene expression in leukaemic cells from patients with acute leukaemia. British Journal of Cancer, 66, 266-272.
13. Gsur, A., Zöchbauer, S., Götzl, M., Kyrle, P.A., Lechner, K. & Pirker, R. (1993) Mdr1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leukemia and Lymphoma, 12, 91-94.
14. Hart, S.M., Ganeshaguru, K., Hoffbrand, A.V., Prentice, H.G. & Mehta, A.B. (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia, 8, 2163-2168.
15. List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. & Dalton, W. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology, 11, 1652-1660.
16. Lundeberg, J., Wahlberg, J. & Uhlén, M. (1991) Rapid colourimetric quantification of PCR-amplified DNA. BioTechniques, 10, 68-75.
17. Maruyama, Y., Murohashi, I., Nara, N. & Aoki, N. (1989) Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia. British Journal of Haematology, 72, 357-362.
18. 2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. British Journal of Cancer, 64, 1011-1018.
19. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. & Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal of the National Cancer Institute, 83, 708-712.
20. Ramachandran, C., Mead, D., Wellham, L.L., Sauerteig, A. & Krishan, A. (1995) Expression of drug resistance-associated mdr-1, GST π, and topoisomerase II genes during cell cycle traverse. Biochemical Pharmacology, 49, 545-552.
21. Ross, D.D., Wooten, P.J., Sridhara, R., Ordóñez, J.V., Lee, E.J. & Schiffer, C.A. (1993) Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil and cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood, 82, 1288-1299.
22. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M. & Pastan, I. (1990) MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. British Journal of Haematology, 75, 340-345.
23. Schneider, E., Cowan, K.H., Bader, H., Toomey, S., Schwartz, G.N., Karp, J.E., Burke, P.J. & Kaufmann, S.H. (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85, 186-193.
24. Solary, E., Bidan, J.-M., Calvo, F., Chauffert, B., Caillot, D., Mugneret, F., Gauville, C., Tsuruo, T., Carli, P.-M. & Guy, H. (1991) P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia, 5, 592-597.
25. Sonneveld, P. & Nooter, K. (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. British Journal of Haematology, 75, 208-211.
26. Te Boekhorst, P., Löwenberg, B., Van Kapel, J., Nooter, K. & Sonneveld, P. (1995) Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia, 9, 1025-1051.
27. + acute myeloid leukemia cells. Blood, 82, 3157-3162.
28. Zhou, D.-C., Marie, J.-P., Suberville, A.-M. & Zittoun, R. (1992) Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia, 6, 879-885.